AbbVie’s immunology portfolio, anchored by Rinvoq and Skyrizi, continues to drive revenue growth as the company transitions beyond Humira’s patent cliff. For Q3 2026, global Rinvoq net revenues reached $2.706 billion, reflecting a 23.9% year-over-year increase on a reported basis and a 24.3% operational gain, outpacing the broader immunology segment’s 16.3% rise. This performance stems from expanded label indications across inflammatory conditions, sustained market-share gains, and robust demand in both established and newer therapeutic areas. The company simultaneously lifted full-year adjusted EPS guidance to $13.95–$13.99 after beating consensus estimates, supported by the recent Apogee Therapeutics acquisition that bolsters the late-stage pipeline. Traders are therefore focused on whether these momentum factors push Rinvoq above the specific revenue threshold embedded in the market contract.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено1H6H1D7D30DALL
View resolved

Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы